TB or not TB? - Rifater® may be the answer

&

Tuberculosis is once again top of the list of killer infectious diseases in adults throughout the world. Of particular concern is the rise in the incidence of multidrug-resistant strains of Mycobacterium tuberculosis

One approach to reducing the development of multidrug-resistant TB may lie in improving patient compliance. In answer to this, Marion Merrell Dow has recently launched Rifater® in the US, the only triple combination therapy for the treatment of active TB.